The Commonwealth Medical Association has commended Global Fund’s decision to commit 15 million dollars to deployment of malaria vaccine in sub-Sahara Africa.
Vice President of the Commonwealth Medical Association, Dr Osahon Enabulele who commended the Global Fund’s urged African leaders to also scale up their national programmes.
“I, therefore, hope that this effort by Global Fund, GSK and its funding partners will be taken by the various governments in Africa as another wakeup call to scale up their national malaria control and eradication intervention strategies to more effectively protect Africans from malaria and its devastating complications’’, he said.
He urged African governments to demonstrate increased commitment to the eradication of the disease from the continent and the entire world.
“Despite the current economic climate, I urge the Federal Government of Nigeria and other African governments to make greater commitment to research efforts for development of malaria vaccine. I am convinced that Africa’s long-term success in the global campaign to defeat malaria will be greatly enhanced with improved investments in research for development of an effective vaccine as well as research into other ways of combating emerging threats such as parasite resistance.”
The funding which was secured by the World Health Organisation will be for the first phase of trial of the world class malaria vaccine called RTS,S in Africa in the year 2018.
The vaccine was developed by British drug maker, GlaxoSmithKline (GKS), in partnership with the non-profit PATH Malaria Vaccine Initiative and part-funded by the Bill and Melinda Gates Foundation.